Rafael Holdings Shares Plunge 25% Following Clinical Trial Failure

Key Facts

1Rafael Holdings shares dropped 25% following the announcement that a clinical drug trial failed to meet its primary endpoint.

Rafael Holdings shares dropped 25% following the announcement that a clinical drug trial failed to meet its primary endpoint. Investing.com reported that the sharp sell-off was triggered by the disappointing results, which represent a critical milestone failure for the pharmaceutical firm.

RFL closed at $2.03 on September 29, 2026, after reaching a day high of $2.14 and a low of $2. The significant price action follows the company's report that the trial failed to achieve its intended goals, impacting the overall valuation of the biotech instrument.